161 related articles for article (PubMed ID: 36479065)
1. The prognosis of bladder cancer is affected by fatty acid metabolism, inflammation, and hypoxia.
Xiao Y; Yang J; Yang M; Len J; Yu Y
Front Oncol; 2022; 12():916850. PubMed ID: 36479065
[TBL] [Abstract][Full Text] [Related]
2. Comprehensive
Xu T; Xu W; Zheng Y; Li X; Cai H; Xu Z; Zou Q; Yu B
Front Immunol; 2022; 13():931906. PubMed ID: 35958598
[TBL] [Abstract][Full Text] [Related]
3. Integrative transcriptional characterization of cell cycle checkpoint genes promotes clinical management and precision medicine in bladder carcinoma.
Shi WW; Guan JZ; Long YP; Song Q; Xiong Q; Qin BY; Ma ZQ; Hu Y; Yang B
Front Oncol; 2022; 12():915662. PubMed ID: 36033441
[TBL] [Abstract][Full Text] [Related]
4. Identification of Hypoxia-Related Subtypes, Establishment of Prognostic Models, and Characteristics of Tumor Microenvironment Infiltration in Colon Cancer.
Wang C; Tang Y; Ma H; Wei S; Hu X; Zhao L; Wang G
Front Genet; 2022; 13():919389. PubMed ID: 35783281
[No Abstract] [Full Text] [Related]
5. A Robust Hypoxia Risk Score Predicts the Clinical Outcomes and Tumor Microenvironment Immune Characters in Bladder Cancer.
Liu Z; Tang Q; Qi T; Othmane B; Yang Z; Chen J; Hu J; Zu X
Front Immunol; 2021; 12():725223. PubMed ID: 34484235
[TBL] [Abstract][Full Text] [Related]
6. Development and Validation of a Hypoxia-Related Signature for Predicting Survival Outcomes in Patients With Bladder Cancer.
Zhang F; Wang X; Bai Y; Hu H; Yang Y; Wang J; Tang Y; Ma H; Feng D; Li D; Han P
Front Genet; 2021; 12():670384. PubMed ID: 34122523
[TBL] [Abstract][Full Text] [Related]
7. Construction of prognostic signature of breast cancer based on N7-Methylguanosine-Related LncRNAs and prediction of immune response.
Cao J; Liang Y; Gu JJ; Huang Y; Wang B
Front Genet; 2022; 13():991162. PubMed ID: 36353118
[No Abstract] [Full Text] [Related]
8. Identification of a combined apoptosis and hypoxia gene signature for predicting prognosis and immune infiltration in breast cancer.
Ren X; Cui H; Wu J; Zhou R; Wang N; Liu D; Xie X; Zhang H; Liu D; Ma X; Dang C; Kang H; Lin S
Cancer Med; 2022 Oct; 11(20):3886-3901. PubMed ID: 35441810
[TBL] [Abstract][Full Text] [Related]
9. Oncogenic signaling pathway-related long non-coding RNAs for predicting prognosis and immunotherapy response in breast cancer.
Li H; Liu H; Hao Q; Liu X; Yao Y; Cao M
Front Immunol; 2022; 13():891175. PubMed ID: 35990668
[TBL] [Abstract][Full Text] [Related]
10. A Novel Pyroptotic and Inflammatory Gene Signature Predicts the Prognosis of Cutaneous Melanoma and the Effect of Anticancer Therapies.
Xu Y; Chen Y; Niu Z; Xing J; Yang Z; Yin X; Guo L; Zhang Q; Qiu H; Han Y
Front Med (Lausanne); 2022; 9():841568. PubMed ID: 35492358
[TBL] [Abstract][Full Text] [Related]
11. Derivation and Comprehensive Analysis of Aging Patterns in Patients with Bladder Cancer.
Wang B; Tong F; Zhai C; Wang L; Liu Y; Wang J
Dis Markers; 2021; 2021():3385058. PubMed ID: 34721733
[TBL] [Abstract][Full Text] [Related]
12. Hypoxic Characteristic Genes Predict Response to Immunotherapy for Urothelial Carcinoma.
Hong S; Zhang Y; Cao M; Lin A; Yang Q; Zhang J; Luo P; Guo L
Front Cell Dev Biol; 2021; 9():762478. PubMed ID: 34901008
[No Abstract] [Full Text] [Related]
13. A novel immune-related gene pair prognostic signature for predicting overall survival in bladder cancer.
Fu Y; Sun S; Bi J; Kong C; Yin L
BMC Cancer; 2021 Jul; 21(1):810. PubMed ID: 34266411
[TBL] [Abstract][Full Text] [Related]
14. Characterization of the Lipid Metabolism in Bladder Cancer to Guide Clinical Therapy.
Yang YY; Hong SY; Xun Y; Liu CQ; Sun JX; Xu JZ; Xu MY; An Y; He D; Xia QD; Wang SG
J Oncol; 2022; 2022():7679652. PubMed ID: 36131793
[TBL] [Abstract][Full Text] [Related]
15. Identification of novel cuproptosis-related lncRNA signatures to predict the prognosis and immune microenvironment of breast cancer patients.
Jiang ZR; Yang LH; Jin LZ; Yi LM; Bing PP; Zhou J; Yang JS
Front Oncol; 2022; 12():988680. PubMed ID: 36203428
[TBL] [Abstract][Full Text] [Related]
16. A novel risk score based on a combined signature of 10 immune system genes to predict bladder cancer prognosis.
Tang Y; Hu Y; Wang J; Zeng Z
Int Immunopharmacol; 2020 Oct; 87():106851. PubMed ID: 32763782
[TBL] [Abstract][Full Text] [Related]
17. The Pyroptosis-Related Risk Genes APOBEC3D, TNFRSF14, and RAC2 Were Used to Evaluate Prognosis and as Tumor Suppressor Genes in Breast Cancer.
Chen Q; Jun H; Yang C; Yang F; Xu Y
J Oncol; 2022; 2022():3625790. PubMed ID: 36059808
[TBL] [Abstract][Full Text] [Related]
18. Robust pyroptosis risk score guides the treatment options and predicts the prognosis of bladder carcinoma.
Deng D; Liu F; Liu Z; Wu Z; He Y; Zhang C; Zu X; Ou Z; Wang Y
Front Immunol; 2022; 13():965469. PubMed ID: 36090967
[TBL] [Abstract][Full Text] [Related]
19. A novel pyroptosis-related signature predicts prognosis and response to treatment in breast carcinoma.
Yu H; Fu Y; Tang Z; Jiang L; Qu C; Li H; Tan Z; Shu D; Peng Y; Liu S
Aging (Albany NY); 2022 Jan; 14(2):989-1013. PubMed ID: 35085103
[TBL] [Abstract][Full Text] [Related]
20. Construction and verification of a novel hypoxia-related lncRNA signature related with survival outcomes and immune microenvironment of bladder urothelial carcinoma by weighted gene co-expression network analysis.
Cai D; Zhou Z; Wei G; Wu P; Kong G
Front Genet; 2022; 13():952369. PubMed ID: 36118856
[No Abstract] [Full Text] [Related]
[Next] [New Search]
